- Home
- CRVS
as 05-16-2025 4:00pm EST
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | BURLINGAME |
| Market Cap: | 206.5M | IPO Year: | 2016 |
| Target Price: | $16.33 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.99 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.75 - $10.00 | Next Earning Date: | 05-08-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Corvus Pharmaceuticals Inc. News
CRVS Breaking Stock News: Dive into CRVS Ticker-Specific Updates for Smart Investing
Simply Wall St.
8 days ago
Spotlight On Top Penny Stocks For May 2025
MT Newswires
11 days ago
Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $17 From $15, Maintains Outperform Rating
Insider Monkey
11 days ago
Is Corvus Pharmaceuticals, Inc. (CRVS) the Low Risk High Reward Stock Set to Triple by 2030?
MT Newswires
11 days ago
Corvus Pharma Reports 'Favorable' Interim Phase 1 Results in Atopic Dermatitis Trial; Shares Surge Premarket
GuruFocus.com
11 days ago
Corvus Pharmaceuticals Inc (CRVS) Q1 2025 Earnings Call Highlights: A Turnaround with Promising ...
Associated Press Finance
11 days ago
Corvus: Q1 Earnings Snapshot
GlobeNewswire
11 days ago
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results
GlobeNewswire
11 days ago
Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Compare CRVS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CRVS Corvus Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.